Description of a Triad of Rare Malignancies in a Single Patient

David Fackrell,Yen Yeo,Nawaz Walji

doi:10.4236/crcm.2015.43023

David Fackrell, Yen Yeo + Show 1 more

Open Access

https://doi.org/10.4236/crcm.2015.43023

Copy DOI

Abstract

We describe the case of a patient diagnosed with a rhabdomyosarcoma and two distinctly separate non-epithelial ovarian cancers. Granulosa cell tumour and Sertoli-Leydig tumour are rare tumours accounting for less than 10% of all ovarian malignancies. Rhabdomyosarcoma is also rare and more commonly seen in childhood. We link these tumours to a mutation in the forkhead transcription factor proteins.

Highlights

Non-epithelial ovarian cancers (NEOC) account for less than 10% of all ovarian malignancies; the aetiology of these rare tumours remains largely unknown
We describe the case of a patient diagnosed with a rhabdomyosarcoma and two distinctly separate NEOC
A report by Missiaglia et al [9] included 171 patients with alveloar rhabdomyosarcoma, including patients with non-metastatic disease. They reported that the subset with PAX3/FOXO1 mutation had a significantly poorer outcome compared with the PAX7/FOXO1 mutation or the fusion-negative group

Summary

Introduction

Non-epithelial ovarian cancers (NEOC) account for less than 10% of all ovarian malignancies; the aetiology of these rare tumours remains largely unknown. We describe the case of a patient diagnosed with a rhabdomyosarcoma and two distinctly separate NEOC. Clinical examination revealed a right sided abdominal mass. The histo-pathology report, reviewed for a second opinion at a reference centre, confirmed a granulosa cell tumour (GCT). No adjuvant treatment was required and the patient remained under clinical surveillance. (2015) Description of a Triad of Rare Malignancies in a Single Patient. In 2005 a surveillance pelvic ultrasound scan reported the presence of an asymptomatic left ovarian cystic mass. Histo-pathology reported an intermediately differentiated Sertoli-Leydig cell tumour, FIGO stage 1. No adjuvant treatment was advocated and the patient remains under clinical surveillance.

Discussion

Findings

Conclusion